ZNF891: A Potential Drug Target and Biomarker for the Treatment of Solid Tumors

Target Name: ZNF891

NCBI ID: G101060200

ZNF891

Other Name(s): ZN891_HUMAN | hCG1646157 | zinc finger protein 891 | Zinc finger protein 891

ZNF891: A Potential Drug Target and Biomarker for the Treatment of Solid Tumors

Solid tumors are a leading cause of cancer-related deaths worldwide, and their development and progression have a significant impact on a patient's overall quality of life. Despite advances in cancer treatment, there remains a need for new and more effective therapies to address the growing number of treatment-resistant tumors. ZNF891, a nuclear factor of activated T cells (NFAT) gene, has been identified as a potential drug target and biomarker for the treatment of solid tumors.

The Nuclear Factor of Activated T Cells (NFAT) gene is a key regulator of the T cell development and function. It is composed of four subunits, ZNF214, ZNF217, ZNF231, and ZNF235, which are involved in the regulation of DNA replication, gene expression, and cellular processes essential for T cell development, such as growth, differentiation, and survival. ZNF891 is a single-copy gene located on chromosome 1p36.1, and it is a key regulator of T cell development and function.

Several studies have demonstrated that changes in ZNF891 gene expression levels have a significant impact on T cell development and function. For example, studies have shown that ZNF891 plays a role in regulating the development of T cell plasticity, which is the ability of T cells to differentiate into different functional subpopulations. ZNF891 has also been shown to regulate the survival and proliferation of T cells, which is crucial for their ongoing function in the immune system.

In addition to its role in T cell development and function, ZNF891 has also been shown to play a role in the regulation of cellular processes that are essential for the survival and growth of solid tumors. For example, studies have shown that ZNF891 is involved in the regulation of cell apoptosis, which is the process by which cells undergo programmed cell death in response to environmental stressors, such as exposure to chemotherapy drugs. ZNF891 has also been shown to play a role in the regulation of angiogenesis, which is the process by which new blood vessels are formed to support tumor growth.

Given its role in T cell development and function, as well as its involvement in the regulation of cellular processes that are essential for the survival and growth of solid tumors, ZNF891 is a promising candidate for drug targeting. Studies have shown that ZNF891 can be expressed and activated in a variety of solid tumor types, including breast, lung, and ovarian cancers. Additionally, ZNF891 has been shown to be involved in the regulation of cellular processes that are critical for the development and progression of these tumors.

Furthermore, ZNF891 has also been shown to be involved in the regulation of angiogenesis, which is a process that is critical for the growth and survival of solid tumors. Angiogenesis is the process by which new blood vessels are formed to support tumor growth, and it is a crucial factor in the development and progression of many solid tumors. ZNF891 has been shown to play a role in the regulation of angiogenesis by regulating the production and function of endothelial cells, which are responsible for the formation of new blood vessels.

In conclusion, ZNF891 is a promising candidate for drug targeting and biomarker for the treatment of solid tumors. Its role in T cell development and function, as well as its involvement in the regulation of cellular processes that are essential for the survival and growth of solid tumors, make it an attractive target for drug development. Further studies are needed to confirm its potential as a drug target and biomarker, as well as to determine its safety and efficacy in clinical trials.

Protein Name: Zinc Finger Protein 891

Functions: May be involved in transcriptional regulation

The "ZNF891 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZNF891 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets